Cannabinoids, as biomarkers and therapeutic drugs, in reproduction/infertility and cancer
Although the application of medical marijuana and cannabinoid drugs is controversial, it is part of modern-day medicine. To date, cannabinoids are allowed in palliative care, but the increasing number of preclinical studies indicate their anticancer properties. However, data are limited regarding adverse events and safety particularly in risk groups such as pregnant women.
Therefore, we are focused in the study of cannabinoids consumption impact in the endocannabinoid signalling within the dynamics of tissue turnover in the maternal-foetal interface, providing valuable information for managing pregnancy-related diseases and infertility. In addition, we are interested in the evaluation of cannabinoids as anticancer agents, which can exhibit synergistic potential with conventional therapies.
The fundamental role of the endocannabinoid system in endometrium and placenta: implications in pathophysiological aspects of uterine and pregnancy disorders.
Maia J., Fonseca B. M., Teixeira N., Correia-da-Silva G.
Hum Reprod Update 2020
Cannabinoid-induced cell death in endometrial cancer cells: involvement of TRPV1 receptors in apoptosis.
Fonseca B. M., Correia-da-Silva G., Teixeira N.
J Physiol Biochem 2018
Decidual NK cell-derived conditioned medium from miscarriages affects endometrial stromal cell decidualisation: endocannabinoid anandamide and tumour necrosis factor-α crosstalk.
Fonseca B. M., Cunha S. C., Gonçalves D., Mendes A., Braga J., Correia-da-Silva G., Teixeira N.
Hum Reprod 35(2), 265–274. 2020